ENHO Antibody, FITC conjugated

1. Serum adropin concentrations are decreased in Chinese T2DM patients, especially those overweight/obese. Adropin, associated with glucolipid homeostasis and insulin sensitivity, may implicate in the pathogenesis of T2DM. PMID: 29669965
2. The highest adropin concentration was found in patients with P-Ch C (11.7+/-5.7 ng/ml) cirrhosis. PMID: 30260179
3. Data suggest that serum and follicular fluid levels of adropin are down-regulated in women with PCOS (polycystic ovary syndrome) compared with control subjects; also, follicular fluid levels of adropin are lower than serum levels of adropin. PMID: 28937295
4. significant association between maternal and umbilical adropin levels and the presence and severity of preeclampsia PMID: 28672759
5. Adropin is coupled with biological clock activity. In mouse liver, ENHO expression has a diurnal rhythm that peaks at the end of maximal nutrient intake in the dark. The nuclear receptors ROR-alpha/gamma and Rev-erb may couple adropin synthesis with circadian rhythms in carbohydrate and lipid metabolism.In humans, associations between plasma adropin concentrations and LDL-C suggest a link with hepatic lipid metabolism. PMID: 29331507
6. An increase in maternal serum adropin level was found in preeclampsia. PMID: 28501281
7. Analysis of midluteal endometrial biopsies revealed an inverse correlation between endometrial EOGT and ENHO expression and body mass index. Obesity impairs the EOGT-adropin axis in decidual cells, which in turn points toward a mechanistic link between metabolic disorders and adverse pregnancy outcome. PMID: 29244071
8. Serum adropin concentrations are negatively associated with renal function. PMID: 27546995
9. High adropin expression is associated with polycystic ovary syndrome. PMID: 26969461
10. There were no significant differences among the groups of systemic sclerosis (SSc) and controls in terms of ENHO gene expressions. There was no significant difference between the limited and diffuse cutaneous subtypes of SSc in terms of serum adropin level and ENHO gene expression. Moreover, serum adropin level and ENHO gene expression were not associated with the disease activity and severity indexes. PMID: 27079850
11. Enho mutations plays a critical role in activating endothelial cells during neutrophil recruitment and neutrophil-endothelium cell interactions under IL-1 and TNF-alpha-induced vascular inflammation and increases susceptibility to MPOANCA associated lung injury. PMID: 27333037
12. In HD patients, lower plasma adropin concentration is associated with dyslipidemia. Major homozygosity of RXRA seems to have an opposite effect on plasma adropin compared with that of ENHO rs2281997 PMID: 27449397
13. Data suggest that serum adropin (ENHO) levels in normal, overweight, and obese adults negatively correlate with vascular stiffness (using common carotid artery) and adiposity (using abdominal visceral fat), and positively correlate with plasma nitric oxide levels (using nitrite/nitrate) and cardiorespiratory fitness; aerobic exercise training up-regulates serum adropin. PMID: 27897440
14. The adropin levels of metabolic syndrome, obesity, and control groups also showed no difference PMID: 26226125
15. Circulating adropin levels were determined lower in patients with endometrial cancer than in a control group. PMID: 26172926
16. Lipids originating either from the diet or from endogenous production appear to positively affect plasma adropin concentrations in humans. PMID: 26435060
17. Serum adropin levels were significantly lower in obese children; however, there was no correlation between serum adropin levels and blood pressure variables. PMID: 26030787
18. Adropin as a novel energy factor likely has the ability to regulate blood pressure PMID: 25913544
19. Serum adropin level was negatively correlated with carotid beta-stiffness and positively correlated with plasma NOx level and cardiorespiratory fitness PMID: 26371163
20. Adropin levels are lower in patients with late saphenous vein graft occlusion and these reduced adropin levels, together with other factors, may lead to saphenous vein graft occlusion PMID: 25282140
21. decreased serum adropin levels are associated with the presence of acute myocardial infarction in coronary artery disease patients PMID: 24731968
22. Assessment of serum adropin concentrations may provide a reliable indicator of fatty liver disease in obese adolescents PMID: 24468600
23. cord blood adropin levels were positively correlated with gestational age and placental weight but not with other fetal growth parameters. PMID: 24284417
24. Plasma adropin levels were found to be a new marker for diagnosing endothelial dysfunction in type 2 diabetes mellitus. PMID: 24113736
25. Release of adropin in the fed condition regulates fuel selection in skeletal muscle, promoting glucose oxidation over fat oxidation. The molecular mechanisms of adropin's effects involve acetylation (suggesting inhibition) of the transcriptional co-activator PGC1alpha, reducing PDK4 and CPT1B activity. Increased PGC1alpha acetylation by adropin may be mediated by inhibiting Sirtuin-1 (SIRT1), a PGC1alpha deacetylase. PMID: 24848071
26. The mean maternal and cord serum adropin in a gestational diabetes mellitus group were significantly lower than those of control women (P=0.01 and P<0.001, respectively). PMID: 23314506
27. Adropin is an independent risk factor for cardiac syndrome X (CSX). PMID: 23356444
28. Although males exhibit higher adropin levels that are reduced by obesity, aging and markers of insulin resistance are associated with low plasma adropin irrespective of sex. PMID: 22872690
29. Plasma adropin levels were examined in 45 men and 85 woman. Adropin levels are higher in men than woman. Obesity is associated with low adropin levels in men. Aging and metabolic risk factors are associated with low adropin levels, irrespective of sex. PMID: 22872690
30. Plasma adropin levels are regulated dietary macronutrients increasing with dietary fat content. Fasting suppresses plasma adropin. Adropin's actions are required for preventing insulin resistance, dyslipidemia and impaired glucose tolerance. PMID: 22318315
31. a potential endothelial protective role of adropin that is likely mediated via upregulation of endothelial NO synthase expression through the VEGFR2-phosphatidylinositol 3-kinase-Akt and VEGFR2-extracellular signal regulated kinase 1/2 pathways. PMID: 20837912
32. Adropin has an endothelial protective function mediated via upregulation of eNOS expression through the VEGFR2-PI3K-Akt and VEGFR2-ERK1/2 pathways. Adropin therapy may thus be useful for limiting diseases characterized by endothelial dysfunction. PMID: 20837912
33. Adropin is the name given to the secreted peptide encoded by the ORF in C9orf165. In mice, it is abundant in liver where it is regulated by dietary macronutrients. Adropin regulates expression of genes involved in lipogenesis and adipogenesis. PMID: 19041763

Show More

Hide All

HGNC: 24838

KEGG: hsa:375704

STRING: 9606.ENSP00000382675

UniGene: Hs.522085